摘要
目的观察利妥昔单抗治疗难治性免疫性血小板减少症(ITP)的临床疗效。方法 10例难治性免疫性血小板减少症患者,静脉注射利妥昔单抗,检测血小板数及淋巴细胞亚群等,观察临床疗效。结果完全反应(CR)30%,有效(R)40%,无效(NR)30%,中位起效时间3周。治疗后所有患者CD19(+)/CD20(+)B细胞数均明显下降。治疗过程中及治疗后12个月内均无严重不良反应。结论利妥昔单抗在治疗难治性免疫性血小板减少症中显示了良好的疗效,是一种安全有效的方法。
Objective To observe the clinical efficacy of rituximab in treatment of refractory ITP.Methods Totally 10 cases of refractory ITP were detected the platelet count and lymphocyte subsets and so on after treated with rituximab,observe the clinical efficacy.Results There were 30% achieved CR,40% achieved R,and 30% NR,the median onset time was 3 weeks.All the cases cd19（＋） / cd20（＋） b cells were significantly decreased after the treatment.And no serious adverse reactions in course of treatment and 12 months after treatment.Conclusions Rituximab in the treatment of refractory ITP shown good efficacy,it was a safe and effective method.
出处
《医药论坛杂志》
2011年第22期41-42,45,共3页
Journal of Medical Forum
